FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2316059449> ?p ?o ?g. }

• W2316059449 endingPage "248" @default.
• W2316059449 startingPage "247.2" @default.
• W2316059449 abstract "<h3>Background</h3> The treatment of rheumatoid arthritis (RA) has been transformed by the development of novel agents targeting biological factors. The idea of “treat to target” has emerged. Early aggressive treatment with methotrexate (MTX) and tumor necrosis factor inhibitors can lead to clinical, radiological and even functional remission in a large proportion of patients with RA. However, there is a population of patients with RA who cannot be treated with MTX. A few clinical studies have reported the efficacy of GLM 100 mg/4 weeks as monotherapy. However, few papers have so far compared GLM 50 mg/4 weeks plus MTX with GLM 100 mg/4 weeks monotherapy. <h3>Objectives</h3> The aim of this study was to compare GLM 50 mg/4 weeks plus MTX with GLM 100 mg/4 weeks monotherapy in patients with RA. <h3>Methods</h3> The subjects were 115 RA patients (92 females; 23 males) who started receiving GLM treatment after September 2011 at Gunma University Hospital and four other institutes (the Gunma Rheumatoid Arthritis Network: GRN). The mean age (range) of the patients was 64 years (17–87), and the mean disease duration was 10 years (0.6–48). Seventy-two of the 114 patients were bio-naïve patients. Eighty-three patients received GLM 50 mg/4 weeks plus MTX (C group) and 32 patients received GLM 100 mg/4 weeks as monotherapy (M group). The mean MTX dosage in the GLM 50 mg/4 weeks plus MTX group was 7.9 mg/week. The erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, matrix metalloproteinase-3 (MMP-3) level, the swollen and tender joint counts and the disease activity score in 28 joints using the ESR (DAS28-ESR) were examined at baseline and six months later. The remission rate and continuation rates at six months were also examined. <h3>Results</h3> The age was significantly higher and the disease duration was significant longer in the M group, however, there were no significant differences in the serum markers or disease activity between the groups at baseline. Additionally, there were also no significant differences in the serum markers or disease activity of the two groups at six months after treatment. The DAS28-ESR remission (DAS28-ESR <2.6) rate was 38% in the C group and 21% in the M group. The continuation rate of GLM at six months was 80% in the C group and 84% in the M group. <h3>Conclusions</h3> In this study, monotherapy improved the disease activity and as well as the combination therapy. These results suggest that GLM 100 mg/4 weeks monotherapy can have a sufficient therapeutic effect in RA patients who cannot use MTX. <h3>References</h3> Smolen, JS., et al. FGolimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009. Takeuchi T. et al. Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks. Ann Rheum Dis. 2013. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4102" @default.
• W2316059449 created "2016-06-24" @default.
• W2316059449 creator A5005513662 @default.
• W2316059449 creator A5006787725 @default.
• W2316059449 creator A5011789623 @default.
• W2316059449 creator A5016115301 @default.
• W2316059449 creator A5023243061 @default.
• W2316059449 creator A5033185902 @default.
• W2316059449 creator A5036290232 @default.
• W2316059449 creator A5040331053 @default.
• W2316059449 creator A5045508721 @default.
• W2316059449 creator A5057964546 @default.
• W2316059449 creator A5060820670 @default.
• W2316059449 creator A5072749673 @default.
• W2316059449 date "2014-06-01" @default.
• W2316059449 modified "2023-09-27" @default.
• W2316059449 title "THU0191 Comparison of Golimumab 50 Mg/4 Weeks plus Methotrexate with Golimumab 100 Mg/4 Weeks Monotherapy in Patients with Rheumatoid Arthritis: Results from the Japanese GRN Multicenter Cohort Study" @default.
• W2316059449 doi "https://doi.org/10.1136/annrheumdis-2014-eular.4102" @default.
• W2316059449 hasPublicationYear "2014" @default.
• W2316059449 type Work @default.
• W2316059449 sameAs 2316059449 @default.
• W2316059449 citedByCount "0" @default.
• W2316059449 crossrefType "journal-article" @default.
• W2316059449 hasAuthorship W2316059449A5005513662 @default.
• W2316059449 hasAuthorship W2316059449A5006787725 @default.
• W2316059449 hasAuthorship W2316059449A5011789623 @default.
• W2316059449 hasAuthorship W2316059449A5016115301 @default.
• W2316059449 hasAuthorship W2316059449A5023243061 @default.
• W2316059449 hasAuthorship W2316059449A5033185902 @default.
• W2316059449 hasAuthorship W2316059449A5036290232 @default.
• W2316059449 hasAuthorship W2316059449A5040331053 @default.
• W2316059449 hasAuthorship W2316059449A5045508721 @default.
• W2316059449 hasAuthorship W2316059449A5057964546 @default.
• W2316059449 hasAuthorship W2316059449A5060820670 @default.
• W2316059449 hasAuthorship W2316059449A5072749673 @default.
• W2316059449 hasConcept C126322002 @default.
• W2316059449 hasConcept C141071460 @default.
• W2316059449 hasConcept C2777077863 @default.
• W2316059449 hasConcept C2777575956 @default.
• W2316059449 hasConcept C2778143017 @default.
• W2316059449 hasConcept C2780132546 @default.
• W2316059449 hasConcept C2781059491 @default.
• W2316059449 hasConcept C2781290027 @default.
• W2316059449 hasConcept C2908647359 @default.
• W2316059449 hasConcept C71924100 @default.
• W2316059449 hasConcept C72563966 @default.
• W2316059449 hasConcept C90924648 @default.
• W2316059449 hasConcept C99454951 @default.
• W2316059449 hasConceptScore W2316059449C126322002 @default.
• W2316059449 hasConceptScore W2316059449C141071460 @default.
• W2316059449 hasConceptScore W2316059449C2777077863 @default.
• W2316059449 hasConceptScore W2316059449C2777575956 @default.
• W2316059449 hasConceptScore W2316059449C2778143017 @default.
• W2316059449 hasConceptScore W2316059449C2780132546 @default.
• W2316059449 hasConceptScore W2316059449C2781059491 @default.
• W2316059449 hasConceptScore W2316059449C2781290027 @default.
• W2316059449 hasConceptScore W2316059449C2908647359 @default.
• W2316059449 hasConceptScore W2316059449C71924100 @default.
• W2316059449 hasConceptScore W2316059449C72563966 @default.
• W2316059449 hasConceptScore W2316059449C90924648 @default.
• W2316059449 hasConceptScore W2316059449C99454951 @default.
• W2316059449 hasIssue "Suppl 2" @default.
• W2316059449 hasLocation W23160594491 @default.
• W2316059449 hasOpenAccess W2316059449 @default.
• W2316059449 hasPrimaryLocation W23160594491 @default.
• W2316059449 hasRelatedWork W1973836240 @default.
• W2316059449 hasRelatedWork W2100586280 @default.
• W2316059449 hasRelatedWork W2108419636 @default.
• W2316059449 hasRelatedWork W2158058290 @default.
• W2316059449 hasRelatedWork W2335222533 @default.
• W2316059449 hasRelatedWork W2397887758 @default.
• W2316059449 hasRelatedWork W4242839550 @default.
• W2316059449 hasRelatedWork W4256594459 @default.
• W2316059449 hasRelatedWork W4307489660 @default.
• W2316059449 hasRelatedWork W46945369 @default.
• W2316059449 hasVolume "73" @default.
• W2316059449 isParatext "false" @default.
• W2316059449 isRetracted "false" @default.
• W2316059449 magId "2316059449" @default.
• W2316059449 workType "article" @default.